|
| |
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online September 23, 2003
Review Article |
Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine
1 Uniformed Services University of the Health Sciences, Bethesda, MD 20814,
USA
2 Sanaria Inc., Rockville, MD 20852, USA
* Author for correspondence (e-mail: slhoffman{at}sanaria.com)
Accepted 17 July 2003
Annually, malaria causes >300 million clinical cases and 1 million deaths, is responsible for the loss of >1% of gross domestic product (GDP) in Africa and is a serious concern for travelers. An effective vaccine could have a dramatic impact on the disease. For 20 years, scientists have tried to develop modern, recombinant `subunit' malaria vaccines. This has been difficult. In fact, there is only one recombinant protein vaccine on the market for any disease, and no vaccines based on synthetic peptides, recombinant viruses, recombinant bacteria or DNA plasmids. Most vaccines are based on attenuated or inactivated whole pathogens or material derived directly from the infectious agent. It is in that context that our recent report summarizing the protection of humans with attenuated Plasmodium falciparum (Pf) sporozoites produced at four different sites over 25 years is important. In studies utilizing live mosquitoes as the vaccine delivery mechanism, there was complete protection against malaria in 93% of volunteers (13/14) and 94% of challenges (33/35). Sanaria's goal is to develop and commercialize a non-replicating, metabolically active Pf sporozoite vaccine.
Three practical questions must be addressed before manufacturing for clinical trials: (1) can one administer the vaccine by a route that is clinically practical; (2) can one produce adequate quantities of sporozoites; and (3) can sporozoites be produced with the physical characteristics that meet the regulatory, potency and safety requirements of regulatory authorities? Once these questions have been answered, Sanaria will demonstrate that the vaccine protects >90% of human recipients against experimental challenge with Pf sporozoites, can be produced with an efficiency that makes it economically feasible, and protects >90% of African infants and children from infection, and thus from severe morbidity and mortality. By producing a vaccine for travelers, Sanaria will provide the infrastructure, regulatory foundation and funds necessary to speed licensure, manufacturing and deployment of the vaccine for the infants and children who need it most.
Key words: malaria vaccine, immunization, Plasmodium falciparum, radiation-attenuated sporozoite, irradiated sporozoite
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Takala, D. Coulibaly, M. A. Thera, A. H. Batchelor, M. P. Cummings, A. A. Escalante, A. Ouattara, K. Traore, A. Niangaly, A. A. Djimde, et al. Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development Science Translational Medicine, October 14, 2009; 1(2): 2ra5 - 2ra5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. VanBuskirk, M. T. O'Neill, P. De La Vega, A. G. Maier, U. Krzych, J. Williams, M. G. Dowler, J. B. Sacci Jr, N. Kangwanrangsan, T. Tsuboi, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design PNAS, August 4, 2009; 106(31): 13004 - 13009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Campbell Malaria Control -- Addressing Challenges to Ambitious Goals N. Engl. J. Med., July 30, 2009; 361(5): 522 - 523. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Othoro, D. Johnston, R. Lee, J. Soverow, J.-C. Bystryn, and E. Nardin Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod Infect. Immun., February 1, 2009; 77(2): 739 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Douradinha, M. M. Mota, A. J. F. Luty, and R. W. Sauerwein Cross-Species Immunity in Malaria Vaccine Development: Two, Three, or Even Four for the Price of One? Infect. Immun., March 1, 2008; 76(3): 873 - 878. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Purcell, S. K. Yanow, M. Lee, T. W. Spithill, and A. Rodriguez Chemical Attenuation of Plasmodium berghei Sporozoites Induces Sterile Immunity in Mice Infect. Immun., March 1, 2008; 76(3): 1193 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Tarun, X. Peng, R. F. Dumpit, Y. Ogata, H. Silva-Rivera, N. Camargo, T. M. Daly, L. W. Bergman, and S. H. I. Kappe A combined transcriptome and proteome survey of malaria parasite liver stages PNAS, January 8, 2008; 105(1): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Donovan, A. S. Messmore, D. A. Scrafford, D. L. Sacks, S. Kamhawi, and M. A. McDowell Uninfected Mosquito Bites Confer Protection against Infection with Malaria Parasites Infect. Immun., May 1, 2007; 75(5): 2523 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yadava, J. Sattabongkot, M. A. Washington, L. A. Ware, V. Majam, H. Zheng, S. Kumar, and C. F. Ockenhouse A Novel Chimeric Plasmodium vivax Circumsporozoite Protein Induces Biologically Functional Antibodies That Recognize both VK210 and VK247 Sporozoites Infect. Immun., March 1, 2007; 75(3): 1177 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. I. KAPPE and P. E. DUFFY Malaria liver stage culture: in vitro veritas? Am J Trop Med Hyg, May 1, 2006; 74(5): 706 - 707. [Full Text] [PDF]
|
|
|
|
|
|
M. R. van Dijk, B. Douradinha, B. Franke-Fayard, V. Heussler, M. W. van Dooren, B. van Schaijk, G.-J. van Gemert, R. W. Sauerwein, M. M. Mota, A. P. Waters, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells PNAS, August 23, 2005; 102(34): 12194 - 12199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Frevert and E. Nardin Arrest in the Liver -- A Genetically Defined Malaria Vaccine? N. Engl. J. Med., April 14, 2005; 352(15): 1600 - 1602. [Full Text] [PDF]
|
|
